Published in Cancer Gene Ther on January 01, 2004
Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity. Mol Ther (2010) 0.88
p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication. Nucleic Acids Res (2009) 0.84
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther (2009) 0.81
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol (2012) 5.86
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (2010) 4.72
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol (2010) 2.71
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 2.45
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol (2009) 2.27
Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol (2003) 2.24
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews. Alcohol Alcohol (2013) 2.20
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology (2011) 2.05
Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol (2002) 1.99
The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat Cell Biol (2011) 1.99
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 1.97
Involvement of TRAIL and its receptors in viral hepatitis. FASEB J (2002) 1.97
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol (2008) 1.92
Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem (2003) 1.91
Management of major postsurgical gastroesophageal intrathoracic leaks with an endoscopic vacuum-assisted closure system. Gastrointest Endosc (2009) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Hepatic gas gangrene following liver transplantation. Liver Transpl (2007) 1.85
Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A (2011) 1.85
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care (2011) 1.84
IKK mediates ischemia-induced neuronal death. Nat Med (2005) 1.83
Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. J Biol Chem (2002) 1.82
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol (2010) 1.78
Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation (2004) 1.69
Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol (2013) 1.67
NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 1.67
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 1.63
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 1.59
Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology (2002) 1.58
NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res (2005) 1.57
Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One (2011) 1.57
Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology (2007) 1.57
TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone (2009) 1.55
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care (2009) 1.54
Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol (2012) 1.53
Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets (2009) 1.52
Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology (2005) 1.51
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST). World J Surg Oncol (2008) 1.49
Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol (2012) 1.49
α-1-antitrypsin inhibits acute liver failure in mice. Hepatology (2014) 1.49
Hepatocyte growth factor/c-Met signalling is important for the selection of transplanted hepatocytes. Gut (2012) 1.48
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47